AI-generated summary
The authors reviewed 17 studies of photobiomodulation for hearing loss, covering 327 animals, 30 humans and 40 animal specimens. They report that outcomes appeared better with wavelengths between 800 and 830 nm and longer exposure, but the included studies were mostly non-randomized controlled trials. The authors state that higher-level evidence is needed to verify these findings.
- Studies included
- 17
- Who or what was studied
- Human and animal subjects (327 animals in 11 studies, 30 humans in 1 study, and 40 animal specimens in 5 studies) with hearing loss treated with photobiomodulation therapy
- Wavelengths
- 908, 810, 532, 635, 830, 808 nm
- Limits stated in the abstract
- Evidence is mainly from non-randomized controlled trials, and heterogeneity in reported parameters and outcomes makes direct comparison difficult.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objectives
To assess outcomes associated with photobiomodulation therapy (PBMT) for hearing loss in human and animal studies.
Design
Systematic review and narrative synthesis in accordance with PRISMA guidelines.
Setting
Data bases searched: MEDLINE, EMBASE, CENTRAL, ClinicalTrials.gov and Web of Science. No limits were placed on language or year of publication. Review conducted in accordance with the PRISMA 2020 statement.
Participants
All human and animal subjects treated with PBMT for hearing loss.
Main Outcome Measures
Pre- and post-PBMT audio metric outcomes.
Results
Searches identified 122 abstracts and 49 full text articles. Of these, 17 studies met the inclusion criteria, reporting outcomes in 327 animals (11 studies), 30 humans (1 study), and 40 animal specimens (5 studies). PBMT parameters included 6 different wavelengths: 908 nm (1 study), 810 nm (1 study), 532 & 635 nm (1 study), 830 nm (3 studies), 808 nm (11 studies). The duration ranged from 4 to 60 minutes in a session, and the follow-up ranged from 5-28 days. Outcomes improved significantly when wavelengths within the range of 800-830 nm were used, and with greater duration of PBMT exposure. Included studies predominantly consisted of non-randomized controlled trials (10 studies).
Conclusions
Hearing outcomes following PBMT appear to be superior to no PBMT for subjects with hearing loss, although higher level evidence is required to verify this. PBMT enables concentrated, focused delivery of light therapy to the inner ear through a non-invasive manner with minimal side effects. As a result of heterogeneity in reporting PBMT parameters and outcomes across the included studies, direct comparison is challenging.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 908 nm, 810 nm, 635 nm, 830 nm, 808 nm, 800-830 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Systematic review, Heterogeneity. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.